These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8568275)

  • 1. Evidence for distinct contributions of heavy and light chains to restriction of antibody recognition of the HIV-1 principal neutralization determinant.
    Watkins BA; Davis AE; Fiorentini S; di Marzo Veronese F; Reitz MS
    J Immunol; 1996 Feb; 156(4):1676-83. PubMed ID: 8568275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
    Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
    J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
    Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display library.
    Ames RS; Tornetta MA; McMillan LJ; Kaiser KF; Holmes SD; Appelbaum E; Cusimano DM; Theisen TW; Gross MS; Jones CS
    J Immunol; 1995 Jun; 154(12):6355-64. PubMed ID: 7759873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial expression of neutralizing mouse monoclonal antibody Fab fragments to Hantaan virus.
    Liang M; Chu YK; Schmaljohn C
    Virology; 1996 Mar; 217(1):262-71. PubMed ID: 8599211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
    Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation.
    Figini M; Marks JD; Winter G; Griffiths AD
    J Mol Biol; 1994 May; 239(1):68-78. PubMed ID: 8196048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable region gene utilization and mutation in a group of neutralizing murine anti-human immunodeficiency virus type 1 principal neutralizing determinant antibodies.
    Pirofski LA; Thomas EK; Scharff MD
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):41-9. PubMed ID: 7678971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antigen/antibody specificity exchanger: a new peptide based tool for re-directing antibodies of other specificities to recognize the V3 domain of HIV-1 gp120.
    Sällberg M; Sherefa K; Zhang ZX
    Biochem Biophys Res Commun; 1994 Dec; 205(2):1386-90. PubMed ID: 7802674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection.
    Ditzel HJ; Itoh K; Burton DR
    J Immunol; 1996 Jul; 157(2):739-49. PubMed ID: 8752924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural studies of human HIV-1 V3 antibodies.
    Stanfield RL; Wilson IA
    Hum Antibodies; 2005; 14(3-4):73-80. PubMed ID: 16720977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of the gp120 superantigen-binding site on human immunoglobulins.
    Karray S; Juompan L; Maroun RC; Isenberg D; Silverman GJ; Zouali M
    J Immunol; 1998 Dec; 161(12):6681-8. PubMed ID: 9862697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies.
    Burlingham WJ; Jankowska-Gan E; DeVito-Haynes L; Fechner JH; Hogan KT; Claas FH; Mulder A; Wang X; Ferrone S
    J Immunol; 1998 Dec; 161(12):6705-14. PubMed ID: 9862700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies.
    Sharon M; Görlach M; Levy R; Hayek Y; Anglister J
    Protein Expr Purif; 2002 Apr; 24(3):374-83. PubMed ID: 11922753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains.
    Tous GI; Wei Z; Feng J; Bilbulian S; Bowen S; Smith J; Strouse R; McGeehan P; Casas-Finet J; Schenerman MA
    Anal Chem; 2005 May; 77(9):2675-82. PubMed ID: 15859580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
    Burioni R; Bugli F; Mancini N; Rosa D; Di Campli C; Moroncini G; Manzin A; Abrignani S; Varaldo PE; Clementi M; Fadda G
    Virology; 2001 Sep; 288(1):29-35. PubMed ID: 11543655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Only selected light chains combine with a given heavy chain to confer specificity for a model glycopeptide antigen.
    Czerwinski M; Siemaszko D; Siegel DL; Spitalnik SL
    J Immunol; 1998 May; 160(9):4406-17. PubMed ID: 9574545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.